Background/Aims: Administration of a lactic acid bacterial strain, Lactococcus lactis subsp. lactis JCM 5805 (LC-Plasma), is reported to prevent viral infection via activation of plasmacytoid dendritic cells in mouse and human studies. As it is assumed that LC-Plasma is taken in excess when it is commercially provided as a supplement, we conducted a trial using capsules to give 250 mg LC-Plasma (5 times the effective anti-viral dose) every day for four weeks to healthy volunteers to investigate the safety of excessive intake of LC-Plasma. Trial Design: A randomized, double-blind, placebo-controlled, parallel-group trial was conducted. Methods: Forty healthy subjects were randomly assigned to the LC-Plasma group (daily intake of five capsules containing 50 mg heat-killed LC-Plasma cells per capsule) or the placebo group (daily intake of five placebo capsules with no LC-Plasma). Physical, hematological, biochemical and urinary examinations and medical interviews were used to evaluate safety. Results: No abnormal differences were observed after excessive intake of LC-Plasma capsules when compared to the intake of placebo capsules. Conclusions: There are no safety concerns associated with the excessive intake of heat-killed LC-Plasma capsules.
Introduction
Lactic acid bacteria (LAB) have been traditionally used in the production of fermented foods, such as yogurt and cheese, and are regarded as highly safe food materials. It is reported that LAB have many health functions, such as the regulation of intestinal cells, immune cells and microbiota, and they have been used in the production of many functional health foods [1] [2] . We previously found that Lactococcus lactis strain Plasma (LC-Plasma), which is a synonym of Lactococcus lactis subsp. lactis JCM 5805, stimulated and activated plasmacytoid dendritic cells (pDC), regardless of whether they were live or heat-killed [3] .
pDC are immune cells, responsible for early reaction to viral infection and play a key role in preventing the proliferation and spread of viruses by production of type I interferons, a key factor in various immune reactions against viruses [4] [5]. We previously reported that LC-Plasma induced the production of interferon-α (IFN-α) in an in vitro study [3] and prevented viral infection in mouse and human studies [6] - [11] . In addition, oral administration of LC-Plasma significantly suppressed lung inflammation and death caused by parainfluenza virus infection in mice via enhancement of lung anti-viral immunity [6] .
LC-Plasma also alleviated the following symptoms of rotaviral infection: weight loss, aggravation of fecal scores and rotavirus outgrowth in mice via increasing mature pDC in the small intestine [7] . In a clinical trial, the expression levels of anti-viral genes in human peripheral blood mononuclear cells (PBMC) stimulated by inactivated human influenza virus A/H1N1 (A/PR/8/34) were higher in the subjects who took LC-Plasma compared with subjects who did not take LC-Plasma [8] . In other clinical studies, the intake of yogurt or supplement containing 50 mg (1.0 × 10 11 cells or more) of LC-Plasma activated human pDC and alleviated the symptoms of flu and common cold [9] [10] [11] . Although it was demonstrated that the intake of 50 mg (1.0 × 10 11 cells or more) of LC-Plasma did not produce any safety concerns, it is assumed that LC-Plasma is taken in excess when it is provided as a supplement. To investigate the safety of excessive intake of LC-Plasma, we conducted a trial where healthy volunteers ingested capsules containing 250 mg LC-Plasma (5 times the effective anti-viral dose) every day for four weeks. 
Subjects and Method

Subjects
This trial was conducted at Shinagawa Season Terrace Health Care Clinic.
Healthy male and female adult volunteers (20 to 64 years old) were recruited in May 2017 by KSO Corporation. All subjects were provided a sufficient explanation regarding the trial including the trial purpose, contents, methods, and expected adverse events. Written informed consent was obtained from all volunteers before the start of the trial. The exclusion criteria were as follows: excessive alcohol-drinking behavior; unable to abstain from drinking alcohol from two days before each examination; chronic illness and regular use of medication;
under treatment or with a history of serious disease (e.g., diabetes, liver disease, kidney disease or heart disease), thyroid gland disease, adrenal gland disease, or other metabolic disorder; any food allergy; under treatment for or with a history of hay fever; under treatment for or with a history of inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease); history of digestive disease affecting digestion or absorption; frequent diarrhea after ingesting dairy products; under treatment for or with a history of drug addiction or alcoholism; possible pregnancy, pregnancy or lactating; unfavorable blood test result at the baseline period; participation or possible participation in another clinical trial using any other food, medicine or cosmetics during this trial; any other reason for ineligibility as judged by the principal investigator.
Sample size was determined to be twenty subjects for each group: guidelines from the Japan Society of Health and Nutrition Food Association recommend at least twenty subjects when conducting a single safety trial [12] .
Trial Design
The trial design was a randomized, double-blind, placebo-controlled, parallel group comparison experiment, conducted from May to July 2017. The baseline period before capsule intake was two weeks, capsule intake period was four weeks, and the follow-up observation period after the completion of intake was two weeks.
Subjects were randomly divided into two groups (the LC-Plasma group or placebo group) containing 20 subjects each by the person responsible for statistical analysis so that no bias was generated in the baseline data (sex, age or BMI).
Subjects consumed either five LC-Plasma capsules containing 50 mg (1.0 × 10 11 or more) of heat-killed LC-Plasma per capsule or five placebo capsules that did not contain LC-Plasma, daily for four weeks. Capsules were consumed at any time of the day during the intake period. Capsules were manufactured under the responsibility of Kirin Co., Ltd. The placebo capsules were made from the same materials and according to the same prescription as the LC-Plasma capsules except that LC-Plasma was replaced with cornstarch. Neither the investigators nor the subjects could distinguish between the capsules. The allocation table was sealed and stored securely by the controller; in addition, the capsule codes were blinded and the data set was locked until all analyses were complete. The examinations included: physical examination (height, weight, body mass index (BMI), systolic blood pressure, diastolic blood pressure, and pulse rate), hematological examination (white blood cell count, red blood cell count, hemoglobin Capsule intake, physical health, living conditions and the intake of health food products and medicines were listed in the subject's diary from fourteen days before the start of capsule intake (in week 0) and until the day before the medical examination during the follow up observation period (in week 6). All meals (including alcohol) ingested during the period from week 0 until week 6 were recorded in a dietary diary. In addition, the contents of meals taken during the period from 7 days before the day of examinations in week 0, week 2, week 4 and week 6 (28 days in total) were recorded in detail in the dietary diary. The records in the diary were checked on the day of each visit date, and subjects were strictly guided if any violations such as surfeit were found.
Statistical Analysis
The mean and standard deviation were calculated for all parameters measured at the baseline period before intake. Statistical analysis was performed by one-way analysis of variance (ANOVA) and the measured values were tabulated (Table   1 (a)). Cross-tabulation tables were prepared for data on gender and qualitative urinalysis, and the results of qualitative urinalysis were scored and analyzed by Wilcoxon's rank sum test (Table 1 and Table 2 ).
The mean and standard deviation were calculated for all parameters measured in each group. Statistical analysis was performed by paired t-test (two-tailed test)
for comparison of the data obtained at the start of ingestion (in week 0), and those obtained at the examination in weeks 2, 4 (intake period) and 6 (at the end of the follow up). In addition, statistical analysis was conducted using unpaired mean ± SD mean ± SD mean ± SD Urine protein 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00
Urine glucose 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00 Urobilinogen 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00
Urine bilirubin 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00
Urine ketone body 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00
Occult blood reaction 0.05 ± 0.22 0.00 ± 0.00 0.317 0.03 ± 0.16 p value: Wilcoxon's rank sum test (asymptotic significance probability). Table 6 . Biochemical parameters at the start of intake, during the intake period and during follow up observations for male and female subjects. Table 7 . Urinalysis parameters at the start of intake, during the intake period and during follow up observations for all subjects. 0.00 ± 0.00 1.000
1.000 0.00 ± 0.00 1.000
1.000
Placebo 20 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000
Urobilinogen LC-Plasma 20 0.00 ± 0.00 1.000
0.00 ± 0.00 1.000
Urine bilirubin LC-Plasma 20 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000
1.000 Placebo 20 0.00 ± 0.00 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000
Urine ketone body LC-Plasma 20 0.00 ± 0.00 1.000 0.00 ± 0.00 1.000
1.000 0.20 ± 0.89 0.317 0.317 0.00 ± 0.00 1.000
Occult Wilcoxon's rank sum test (LC-Plasma group vs placebo group) asymptotic significance probability. p value 2: Wilcoxon's signed rank test (vs 0 W) asymptotic significance probability. Table 8 . Urine pH and urine specific gravity at the start of intake, during the intake period and during follow up observations for all subjects. (Table 4 and Table 6 ). Data for the qualitative evaluation parameters were scored and basic statistics were calculated. Statistical analysis was performed by Wilcoxon's signed rank test for comparison of the data obtained at the start of ingestion (in week 0), and those obtained at the examination in weeks 2, 4 (intake period) and 6 (at the end of the follow up). In addition, statistical analysis was conducted by Wilcoxon's rank sum test for comparison of the data at each examination between the LC-Plasma group and placebo group (Table 7 ). All statistical tests were conducted with a significance level of 0.05.
Results
Subject characteristics: The Consolidated Standards of Reporting Trials flow diagram for this trial is shown in Figure 1 . A total of 103 healthy volunteers were initially recruited. Fifty eight subjects were excluded based on the exclusion criteria, three subjects refused to participate and two subjects were not selected. Table 1 (a) and Table 1 (b) show the baseline characteristics of each group. A significant difference between the LC-Plasma group and the placebo group was observed in the levels of LD (LDH), however, this fluctuation in a single parameter is negligible since the primary purpose of the trial is to evaluate the overall safety of excessive intake of LC-Plasma capsules. The trial was conducted as illustrated in Table 1 (a) and Table 1(b). None of the subjects met the predefined discontinuance criteria during the examination period, and thus data obtained from all 40 subjects were included in the analysis. higher LD (LDH) at the start of ingestion and week 4; lower ALP at the start of ingestion and weeks 2, 4 and 6; lower total protein in week 6. The results of the biochemical examinations of male or female subjects are shown in Table 6 . In the male group, compared to the values in week 0, significant changes were observed in the following parameters: in the LC-Plasma group, lower creatinine in week 4, higher uric acid in week 6; in the placebo group, higher uric acid in week 4. In the female group, compared to the values in week 0, significant changes were observed in the following parameters: in the LC-Plasma group, lower γ-GT (g-GTP) in week 4, lower HDL-cholesterol in weeks 4 and 6, lower creatinine in week 4; in the placebo group, higher creatinine in week 2. No significant changes were observed in the other parameters. Although significant changes were observed among several parameters in the biochemical examinations during the trial, these changes were within the range of physiological fluctuation and deemed clinically irrelevant. Based on the biochemical measurements, this was judged to be of no safety concern by the principal investigator.
Urinalysis examinations: The results of the urinalysis (quantitative test and scoring qualitative test) are shown in Table 7 and Table 8 . No significant changes were observed in any of the parameters.
Adverse events: Five adverse events (one event in one subject in the LC-Plasma group and four events in three subjects in the placebo group) were observed during the trial period ( Table 9 ). The principal investigator judged that all of the adverse events were "not related" to the trial capsules because the events were accidental or occurred outside of the intake period.
Discussion
Lactococcus lactis has been traditionally used in foods such as cheese and has been listed in "Qualified Presumption of Safety (QPS)-recommended biological agents intentionally added to food or feed" issued by the European Food Safety Authority [13] . Pharmacokinetics of LC-Plasma is thought that orally admini- g/day indigestible dextrin for twelve weeks were safe [14] . Moreover, products containing LC-Plasma have been marketed as soft drinks and yogurt from Kirin Beverage Co., Ltd. and Koiwai Milk Products Co., Ltd, and no health damage associated with them has been reported.
In this trial, the safety of ingesting LC-Plasma (250 mg/day) for four weeks was assessed in forty subjects. The examinations included physical, hematological, biochemical and urinary examinations and a medical interview. In the urinary examinations, there were no significant changes within the LC-Plasma group and the placebo group when compared to the reference values (week 0) and no significant changes between the LC-Plasma group and the placebo group.
Significant differences and measurements outside the reference range were found in various parameters of the physical, hematological and biochemical examinations but none were considered to be a safety concern by the principal investigator. Significant differences in various parameters were also found between the LC-Plasma group and the placebo group, however, all of these differences were within the range of the reference values and within the range of physiological fluctuation. Thus, these differences were not considered to be a clinical safety concern attributable to the intake of the LC-Plasma capsules. The investigator determined that the adverse events noted in medical interviews by physicians and diary records by subjects were not related to the trial capsules because all of them were accidental or occurred outside of the intake period. Therefore, it was concluded that there are no clinical safety concerns associated with the excessive intake (5 times the anti-viral effective dose) of LC-Plasma.
Conclusion
There are no safety concerns associated with the consumption of heat-killed LC-Plasma (250 mg/day) for four weeks in the results obtained from physical, hematological, biochemical and urinary examinations and medical interviews in a randomized double-blind placebo-controlled parallel-group comparison method using 40 healthy adult males and females.
